Previous 10 | Next 10 |
Image source: The Motley Fool. Abiomed Inc (NASDAQ: ABMD) Q3 2020 Earnings Call Feb 6, 2020 , 8:00 a.m. ET Operator Continue reading
On Thursday, Abiomed (NASDAQ: ABMD) announced its results for its third quarter, delivering a major beat on its bottom-line estimates. The market was expecting $1.09 a share in earnings, but got $1.51 a share instead. Profits were up 57% from a year ago. However, Wall Street was appar...
Abiomed, Inc. (ABMD) Q3 2020 Results Earnings Conference Call February 06, 2020, 08:00 AM ET Company Participants Michael Minogue - Chairman, President and CEO Todd Trapp - VP and CFO Conference Call Participants Raj Denhoy - Jefferies Matt O'Brien - Piper Sandler Daniell...
Abiomed ( ABMD -7.8% ) Q3 results : Revenues: $221.6M (+10.5%). More news on: Abiomed, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Tonix Pharmaceuticals Holding (NASDAQ: TNXP ) -58% on failed Tonmya study . More news on: Tonix Pharmaceuticals Holding Corp., ReWalk Robotics Ltd., Funko, Inc., Stocks on the move, , Read more ...
The following slide deck was published by Abiomed, Inc. in conjunction with their 2020 Q3 earnings Read more ...
BTIG Research has restarted coverage on the following: More news on: Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Healthcare stocks news, , Read more ...
Abiomed (NASDAQ: ABMD ): Q3 Non-GAAP EPS of $1.12 beats by $0.03 ; GAAP EPS of $1.51 beats by $0.42 . More news on: Abiomed, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported third quarter fiscal 2020 revenue of $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019. Operating income was $70...
Abiomed (NASDAQ: ABMD ) is scheduled to announce Q3 earnings results on Thursday, February 6th, before market open. The consensus EPS Estimate is $1.09 (+12.4% Y/Y) and the consensus Revenue Estimate is $226.92M (+13.1% Y/Y). Over the last 2 years, ABMD has beaten EPS estimates ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...